文献速递免疫规划传染病防控与疫情报告

接种PCV13疫苗的儿童仍携带PCV13额外血清型时,其携带密度与接种PCV7疫苗的对照组儿童相似

PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
PubMed 文献 · Vaccine · 2017-01-11

这项在以色列南部开展的随机双盲研究纳入881名接种PCV13和873名接种PCV7的婴儿,在7、12、13、18、24月龄采集鼻咽培养并用半定量法评分。事后分析显示,接种PCV13的儿童若仍携带PCV13独有的6个额外血清型,其携带密度与接种PCV7的对照组相比无显著差异,犹太与贝都因亚组间也无差异。

要点

  • PCV13接种儿童携带PCV13额外血清型时,携带密度与PCV7对照组无显著差异。
  • 犹太与贝都因亚组间携带密度无差异,尽管贝都因受试者携带率更高。
  • 作者认为PCV对携带密度的影响对疫苗成功影响极小或无影响。

核心结论

  • 尽管PCV13相比PCV7通过减少PCV13额外血清型的鼻咽获得而降低疫苗型携带,但本研究缺乏证据表明接种儿童获得这些血清型后携带密度下降。
  • 作者认为,当前分析提示PCV对携带密度的影响对疫苗成功影响极小或无影响。

研究设计与样本

  • 随机双盲研究,在以色列南部开展,纳入犹太和贝都因受试者。
  • 按方案,881名婴儿在2、4、6、12月龄接种PCV13,873名婴儿接种PCV7。
  • 在7、12、13、18、24月龄采集鼻咽培养,采用4象限半定量法平板接种并评分0(阴性)至4(所有平板象限均生长)。
  • 本分析为事后分析,计算各疫苗组总人群及各民族亚组每个血清型及血清型组合的累积定植密度最小二乘均值,并用线性模型推导疫苗组间差异。

主要发现

  • 接种PCV13的儿童若仍携带PCV13独有的6个额外血清型,其携带密度与接种PCV7的对照组相比无显著差异。
  • 犹太与贝都因亚组间携带密度无差异,尽管贝都因受试者携带率更高。

局限性

  • 本研究为事后分析。
  • 作者指出,尽管未观察到对携带密度的影响,但监测数据显示PCV实施后疾病率大幅下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In addition to reducing vaccine-type nasopharyngeal carriage rates, pneumococcal conjugate vaccines (PCVs) may decrease carriage density in vaccinated individuals still carrying vaccine serotypes. However, reduction of carriage density has not been systematically studied. This study compared the effect of PCV13 versus PCV7 on carriage density of the serotypes in PCV13 that are not included in PCV7. METHODS: This randomized, double-blind study was conducted in southern Israel and included Jewish and Bedouin subjects. Per protocol, 881 and 873 infants received PCV13 and PCV7, respectively, at ages 2, 4, 6, and 12months. Nasopharyngeal cultures at ages 7, 12, 13, 18, and 24months were plated using the 4-quadrant semiquantitative method and graded 0 (negative) to 4 (growth in all plate quadrants). In this post hoc analysis, the least squares means of cumulative colonization densities per serotype and serotype combination of the total population and each ethnic subpopulation in each vaccine group were calculated, and differences between vaccine groups derived from a linear model. RESULTS: PCV13-vaccinated children still carrying the 6 additional PCV13 serotypes unique to PCV13 showed no significant differences in carriage density compared with the PCV7-vaccinated control group. No differences in carriage density were shown between Jewish and Bedouin subpopulations despite higher carriage rates among Bedouin subjects. CONCLUSIONS: Although PCV13 vaccination reduces vaccine-type carriage compared with PCV7 vaccination by reducing nasopharyngeal acquisition of the additional PCV13 serotypes as previously reported, the current study lacks evidence of a decrease in carriage density of these serotypes when acquired in vaccinated children. Despite the lack of effect on carriage density observed, surveillance data suggest a dramatic decrease in disease rates after PCV implementation. Thus, the current analysis suggests that PCV's impact on carriage density has minimal or no impact on vaccine success. (www.ClinicalTrials.gov: NCT00508742).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dagan R, Juergens C, Trammel J, et al. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children. Vaccine. 2017. PMID: 28087146. doi:10.1016/j.vaccine.2016.12.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。